Medicine. What are the right targets for psychopharmacology?
about
Glutamatergic deficits and parvalbumin-containing inhibitory neurons in the prefrontal cortex in schizophreniaPsychopharmacology and memoryThe neurobiology of anhedonia and other reward-related deficitsCognitive enhancement in schizophrenia: pharmacological and cognitive remediation approachesMuscarinic agonists for the treatment of cognition in schizophreniaResting EEG in psychosis and at-risk populations--a possible endophenotype?Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophreniaRemoving obstacles in neuroscience drug discovery: the future path for animal models.Developing treatments for cognitive deficits in schizophrenia: the challenge of translation.Anhedonia, avolition, and anticipatory deficits: assessments in animals with relevance to the negative symptoms of schizophreniaAre cross-species measures of sensorimotor gating useful for the discovery of procognitive cotreatments for schizophrenia?Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.The family of sensorimotor gating disorders: comorbidities or diagnostic overlaps?Association between nicotine withdrawal and reward responsiveness in humans and rats.Neural bases of pharmacological treatment of nicotine dependence - insights from functional brain imaging: a systematic review.Moving towards ICD-11 and DSM-V: Concept and evolution of psychiatric classification.Regulation of synaptic plasticity in a schizophrenia model.Future directions for research on youth with bipolar spectrum disordersPharmacogenomics and personalized medicine in neuropsychiatry.In search of a depressed mouse: utility of models for studying depression-related behavior in genetically modified mice.Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia.Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis.Reconceptualizing anhedonia: novel perspectives on balancing the pleasure networks in the human brainBug-eyed and breathless: emerging crises involving valuesThe NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia.Pathophysiologically based treatment interventions in schizophrenia.Next-generation treatments for mental disorders.Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.Identifying phronotypes in psychiatry.Comparing genes and phenomenology in the major psychoses: schizophrenia and bipolar 1 disorder.Clinical course of children and adolescents with bipolar spectrum disorders.Reliability and validity of the CogState battery Chinese language version in schizophrenia.Cure therapeutics and strategic prevention: raising the bar for mental health research.Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.Psychopharmacology of conduct disorder: current progress and future directions.Influence of kynurenine 3-monooxygenase (KMO) gene polymorphism on cognitive function in schizophreniaNeurocognitive outcomes in the Treatment of Early-Onset Schizophrenia Spectrum Disorders study.GABA Targets for the Treatment of Cognitive Dysfunction in SchizophreniaA structure-function mechanism for schizophrenia.Domains of dysfunction in schizophrenia: implications for diagnosis
P2860
Q24649621-BC4F0AA0-BC53-4F9F-A2CB-6F6D23BA61E2Q24655697-1DEE09C9-ED2C-4939-8D2D-8FD45DDD9055Q26853518-3BA11110-C208-489C-B5BA-94B8DF308810Q26864324-417653E5-5D6B-4EE4-BD05-D705F3B2BAB6Q28301970-BBC33B9B-A73C-4956-8FB2-9AEDB4E1C248Q28660572-404B2BB3-70E3-4F33-B569-32EE02F7F420Q28744227-A2EEB571-9DD9-4C1F-9DD9-6F91B274C8D3Q28755229-6D248F64-E92F-413C-B6D4-F66742598445Q30396775-1AF59731-EA09-4278-91C4-29DB1A1DABF4Q30413012-11104462-8339-4415-954D-C8905B0C6C0CQ30473418-CC13EF86-B7B4-49E2-95D5-BA0DC1BE6429Q30489404-19379C4E-EC5E-49F5-BFFA-FC20CD0803FCQ30490231-304A99BF-7AD8-4136-A34B-58B81129EB30Q30625820-F54E2CFC-1617-44CD-9313-FD47C7995B2CQ30655273-18F8E45E-76B4-4D98-A34C-83F18CCBA0B6Q33574486-6D7DD205-B91C-403F-B2CA-CF8BEBBAFA5FQ33948009-3111F97D-8CF4-462F-9455-6E2527890D17Q34063460-84778C82-FAE4-44E1-ADE1-05BA6222122CQ34280025-A5F8636C-2CEF-491B-9100-659B2F771F43Q34292427-B104E4C5-C5FB-45FA-A23A-4F0904C2381FQ34313688-572AB18E-9484-4C08-91BC-1921214A2F61Q34379248-585659BD-EBCE-41C8-B912-01E991D7C603Q34468910-5C542BBC-63DF-4861-9084-C3221BFB581EQ34482116-44084592-AA98-4F3D-8391-8DD94D049940Q34517898-C6C2BA2F-BDC7-4BEF-88FB-C797F9F04713Q34570681-2ED5E5FE-87F2-4986-9603-B9D9579CDA46Q34643734-7F08FAD4-890F-416D-9012-18DAB4CD41E7Q34661875-35886D43-368C-4BDC-B2FE-2DA01B605382Q34689379-15347442-AD0C-487D-B4C3-37C62B603CF8Q34783324-E6F82B83-7BAC-4BD5-8EDC-9D82888FB505Q34814593-CCBC93E3-8260-473D-A617-EC730291353EQ34984648-3FB08E7B-4C37-466D-9AF1-38B0DE43ED73Q35062074-D07C0986-A808-4409-B5D8-1DCDC1F68E75Q35245833-7858FECA-5E43-4025-A1FE-0CABE91A76CBQ35779213-DA329632-AFFE-4DC3-A995-9E0897D3E589Q35892576-7CB8B43E-9293-476B-853C-6C69CDF289CDQ35915533-CE36C437-BC16-4598-9224-E8D759BDED9DQ35916950-761144A9-1A36-4C3E-98B6-99AEAD70E751Q36493182-EFFED7F7-79EF-485B-93EB-EB9CD08764DBQ36575373-73485F39-E4CD-4866-8666-27660FBFAE97
P2860
Medicine. What are the right targets for psychopharmacology?
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Medicine. What are the right targets for psychopharmacology?
@en
type
label
Medicine. What are the right targets for psychopharmacology?
@en
prefLabel
Medicine. What are the right targets for psychopharmacology?
@en
P356
P1433
P1476
Medicine. What are the right targets for psychopharmacology?
@en
P2093
Steven E Hyman
Wayne S Fenton
P304
P356
10.1126/SCIENCE.1077141
P407
P577
2003-01-01T00:00:00Z